Germany’s benefit committee reassesses zolbetuximab for stomach cancer
For one patient group the committee sees an indication of a minor added benefit; for another, no added benefit has been shown.
On 5 November 2026, Germany’s Federal Joint Committee (G-BA) reassessed the added benefit of zolbetuximab (brand name Vyloy). The medicine has been authorised in the EU since September 2024. It is used together with chemotherapy as the first treatment for adults whose adenocarcinoma of the stomach or of the junction with the oesophagus cannot be removed by surgery or has spread. The tumour cells must carry a particular feature, Claudin 18.2, and must not show HER2.
Zolbetuximab had been classified as a medicine for a rare disease. In that case, an added benefit is initially assumed by law. Because sales exceeded the €30 million threshold, it now had to be compared with the usual comparison treatment. The committee distinguishes patients by the marker PD-L1, which shows whether immunotherapy is an option. For tumours with a PD-L1 score (CPS) of 1 or more, no added benefit has been shown. No data were available for a comparison with chemotherapy plus immunotherapy.
For tumours with a PD-L1 score below 1, the committee sees an indication of a minor added benefit compared with chemotherapy alone. An indication is the lowest level of certainty. It is based on a subgroup of 172 people from the GLOW study. With zolbetuximab they lived for a median of 15.5 months, without it 12.1 months. The committee found no relevant differences in symptoms, quality of life or side effects. The decision is the basis for price negotiations, does not change the authorisation, and is not a recommendation for individual patients.
View matching trials
You will find all new trials in the categories Stomach, bowel and glands.
Sources
- Arzneimittel-Richtlinie/Anlage XII: Zolbetuximab (Neubewertung eines Orphan Drugs nach Überschreitung der 30 Millionen Euro-Grenze: Adenokarzinom des Magens oder des gastroösophagealen Übergangs, Claudin (CLDN) 18.2 positiv, HER2-negativ, Erstlinie, Kombination mit fluoropyrimidin- und platinhaltiger Chemotherapie) (opens in a new tab) · Gemeinsamer Bundesausschuss (G-BA) · Accessed on